Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $82,200.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) insider Andrew Combs acquired 60,000 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were bought at an average cost of $1.37 per share, with a total value of $82,200.00. Following the completion of the acquisition, the insider now directly owns 377,623 shares of the company’s stock, valued at $517,343.51. The trade was a 18.89 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Andrew Combs also recently made the following trade(s):

• On Friday, December 20th, Andrew Combs bought 3,075 shares of Prelude Therapeutics stock. The shares were bought at an average price of $1.15 per share, with a total value of $3,536.25.

Prelude Therapeutics Price Performance

NASDAQ:PRLD opened at $1.34 on Friday. Prelude Therapeutics Incorporated has a one year low of $0.80 and a one year high of $6.80. The business has a fifty day moving average price of $1.15 and a 200-day moving average price of $3.08. The firm has a market capitalization of $73.75 million, a price-to-earnings ratio of -0.75 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. The company had revenue of $3.00 million during the quarter. On average, equities research analysts expect that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Prelude Therapeutics in a research note on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Institutional Investors Weigh In On Prelude Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC boosted its position in shares of Prelude Therapeutics by 86.0% in the third quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after purchasing an additional 12,564 shares during the period. XTX Topco Ltd bought a new position in Prelude Therapeutics in the 3rd quarter worth $100,000. Dimensional Fund Advisors LP increased its stake in Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after buying an additional 14,769 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Prelude Therapeutics by 32.2% during the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after acquiring an additional 15,682 shares during the period. Finally, Walleye Capital LLC lifted its position in shares of Prelude Therapeutics by 446.2% in the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after acquiring an additional 67,946 shares in the last quarter. Institutional investors own 79.72% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.